Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for BridgeBio Pharma (BBIO) over the last 5 years, with Q3 2025 value amounting to $6.6 million.

  • BridgeBio Pharma's Cost of Revenue rose 99749.16% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 52454.01%. This contributed to the annual value of $3.9 million for FY2024, which is 5854.46% up from last year.
  • BridgeBio Pharma's Cost of Revenue amounted to $6.6 million in Q3 2025, which was up 99749.16% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Cost of Revenue registered a high of $6.6 million during Q3 2025, and its lowest value of $109000.0 during Q2 2021.
  • For the 5-year period, BridgeBio Pharma's Cost of Revenue averaged around $1.4 million, with its median value being $651000.0 (2023).
  • As far as peak fluctuations go, BridgeBio Pharma's Cost of Revenue tumbled by 5828.5% in 2022, and later skyrocketed by 99749.16% in 2025.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Cost of Revenue stood at $1.6 million in 2021, then tumbled by 58.28% to $647000.0 in 2022, then decreased by 7.57% to $598000.0 in 2023, then soared by 248.49% to $2.1 million in 2024, then skyrocketed by 214.92% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $3.7 million for Q2 2025, and $2.6 million during Q1 2025.